Prostate cancer Posts Page 2 on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Biochemical relapse-free survival outcomes for intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB)

Posted by on Mar 5, 2018 in Prostate cancer | 0 comments

In a nutshell This study examined rates of biochemical relapse after using intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB) in men with low and intermediate stage prostate cancer. This study found that rates of biochemical relapse were low after treatment.  Some background...

Read More

Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.

Posted by on Mar 5, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to identify risk factors of recurrence after prostatectomy in high risk patients. Patients with more risk factors were more likely to experience disease recurrence at five years. Some background Prostatectomy is a treatment option for prostate cancer. The prostate tumor is surgically removed. There are several risk...

Read More

Does age matter? Enzalutamide or bicalutamide for mestastatic castration-resistant prostate cancer patients of different ages

Posted by on Feb 12, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) compared to bicalutamide (Casodex) in castration-resistant metastatic prostate cancer (cancer that does not respond to hormone therapy) patients in different age groups. This study concluded that enzalutamide improved outcomes for...

Read More

To Treat or Not To Treat Cancer: Medical Decision-making

To Treat or Not To Treat Cancer: Medical Decision-making

Posted by on Jan 28, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 10 comments

Cherry Hughes** is an active, energetic 75 year old, still working in the marketing and public relations profession in Great Britain.  Her life is filled with friends and fun.  “I love cooking and eating out.  I am deeply interested in politics.  I love music …I go to jazz clubs.  I love going to France …I have a little apartment...

Read More

PSA response after cabazitaxel treatment is associated with improved progression-free survival in men with metastatic castration-resistant prostate cancer.

Posted by on Jan 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the links between prostate specific antigen (PSA, a protein present in prostate cancer) and survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. This studty concluded that PSA response after cabazitaxel treatment is associated with improved...

Read More

What is Neutropenia?

What is Neutropenia?

Posted by on Jan 21, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 1 comment

There are 1.6 million people diagnosed with cancer in the US each year. Of these, 650,000 receive chemotherapy. Did you know that 60,000 people a year are hospitalized for neutropenia, a common side effect of chemotherapy? One in fourteen die because of it. Of the 650,000 receiving chemotherapy, 104,000 are not aware of neutropenia and 52,000 don’t...

Read More

Emergencies and Illness

Emergencies and Illness

Posted by on Jan 17, 2018 in Blog, Breast cancer, Colorectal cancer, Coronary artery disease, Diabetes mellitus, Hodgkin's lymphoma, Hypertension, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Prostate cancer | 1 comment

After three hurricanes, flooding, fires and mudslides, and now severe cold and snow in the Deep South and throughout the country, the US has had its share of emergencies. Are you prepared? For people who rely on oxygen, who are on dialysis, have diabetes or other serious conditions, it is time to think about putting together some of the essentials.  What...

Read More

Abiraterone acetate and docetaxel with androgen deprivation therapy in high risk and metastatic hormone naive prostate cancer

Posted by on Jan 15, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to find out if androgen deprivation therapy (ADT) is more effective used with docetaxel (Taxotere) or abiraterone (Zytiga). There was no significant difference found between the two treatment options.  Some background Androgen deprivation therapy (ADT) is a treatment used for advanced prostate...

Read More